Immune System Diseases

905 trials 381 recruiting

Filter these 905 trials by phase, country and sponsor.

Open in Search →

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata Patients (Rezolve AA) Ended

2023-509981-39-00 Alopecia Areata 4 2024-11-20
A randomized, controlled study to evaluate LNP023 (iptacopan) in patients with active ANCA-associated vasculitis. Ended

2023-510525-15-00 active antineutrophilic cytoplasmic antibody (ANCA) ass 4 2024-11-18
Apremilast study in children with active oral ulcers associated with Behçet's Disease Ended

2023-503436-40-00 Behcet's disease 5 2024-11-11
Evaluation of TNF-alpha antagonists (infliximab) withdrawal in sarcoidosis Ended

2024-516965-35-00 Immune system disorders 5 2024-10-28
A research study to evaluate the efficacy and safety of cenerimod in subjects suffering from systemic lupus erythematosus Ended

2024-515871-37-00 Moderate to severe systemic lupus erythematosus 5 2024-10-24
A research study to evaluate the effects of a new oral medicine called cenerimod in adults with systemic lupus erythematosus Ended

2024-515870-28-00 Moderate to severe systemic lupus erythematosus 5 2024-10-22
INCA34176-254: A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ru… Ended

2022-502168-19-00 chronic graft-versus-host disease 4 2024-10-22
A Phase 2 Study of Obexelimab in Patients with Systemic Lupus Erythematosus Ended

2024-510584-37-00 Systemic Lupus Erythematosus 4 2024-10-22
A Phase 3 study to evaluate the Efficacy and Safety of Efgartigimod IV in Patients with Acetylcholine Receptor Binding Antibody Seronegative… Ended

2024-511796-15-00 Acetylcholine Receptor Binding Antibody Seronegative Ge 5 2024-10-16
Intravenous immunoglobulin and prednisone vs. prednisone in newly diagnosed myositis: a double blind randomized clinical trial Ended

2024-516057-42-00 Idiopathic inflammatory myopathy 4 2024-10-10
A phase Ib, open-label, ascending dose study with step-up doses to assess safety, tolerability, and pharmacokinetics of PIT565 in participan… Ended

2023-510025-14-00 Systemic Lupus Erythematosus 3 2024-10-08
A study to learn how bimekizumab works in people with moderate to severe plaque psoriasis. Ended

2023-506333-29-00 Moderate to Severe Plaque Psoriasis 11 2024-10-01
Comparing the effectiveness of our tailor-made management approach with routine care from a clinical, patient's as well as an economic point… Ended

2024-511530-12-01 Rheumatoid arthritis according to 2010 criteria 6 2024-10-01
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy,… Ended

2023-505739-12-01 Chronic Inducible Urticaria (CINDU) 5 2024-09-30
RElapse from Mrd Negativity As iNdication for Treatment Ended

2023-510215-18-00 Multiple myeloma 10 2024-09-26
A study to determine if ravulizumab can help preserve kidney function in adults with immunoglobulin A nephropathy (IgAN) Ended

2023-507851-31-00 Immunoglobulin A Nephropathy (IgAN) 5 2024-09-23
Clinical trial to assess the efficacy and safety of a vaccine for grasses and olive tree allergy Ended

2024-514525-34-00 Aetiological treatment of moderate-severe intermitent o 5 2024-08-18
A phase 2 study to investigate the efficacy and safety of CYP‑001 in combination with corticosteroids in adults with high-risk acute graft v… Ended

2022-502673-41-01 High-Risk Acute Graft Versus Host Disease 4 2024-07-29
Selective Treatment of Oral Povorcitinib in Hidradenitis Suppurativa Long-Term Extension Study (STOP-HS LTE) Ended

2023-507204-31-00 Hidradenitis Suppurativa 5 2024-07-26
Phase IIa Proof-of-Concept Study to Investigate the Efficacy, Safety, and Tolerability of FBL-MTX in Patients with Rheumatoid Arthritis Ended

2023-510258-17-00 Rheumatoid arthritis (RA) 4 2024-07-24
A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome Ended

2023-503923-24-00 Sjögren’s Syndrome With Moderate-toSevere Symptom State 5 2024-07-22
Linfociti T virus-specifici per infezioni virali resistenti alla terapia farmacologica dopo trapianto allogenico di cellule staminali emopoi… Ended

2024-518925-14-02 Patients who have received an allogeneic haematopoietic 3 2024-07-17
HOVON 169 CAD: Phase II trial of Zanubrutinib in primary Cold Agglutinin Disease. CaZa study Ended

2023-505746-25-00 Cold agglutinin disease 4 2024-07-16
A Phase 2b Study to Evaluate Eltrekibart in Adults with Moderate to Severe Hidradenitis Suppurativa Ended

2023-505608-43-00 Moderate to Severe Hidradenitis Suppurativa 4 2024-07-04